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Abstract: Post-transcriptional control of gene expression is mediated by RNA-binding 
proteins (RBPs) and small non-coding RNAs (e.g., microRNAs) that bind to distinct 
elements in their mRNA targets. Here, we review recent examples describing the synergistic 
and/or antagonistic effects mediated by RBPs and miRNAs to determine the localisation, 
stability and translation of mRNAs in mammalian cells. From these studies, it is becoming 
increasingly apparent that dynamic rearrangements of RNA-protein complexes could have 
profound implications in human cancer, in synaptic plasticity, and in cellular differentiation. 
Keywords: gene expression; post-transcriptional control; RNA-binding protein; microRNA; 
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1. Introduction 
The post-transcriptional control of gene expression is fundamental for proper cell homeostasis [1]. 
In particular, the fate of messenger RNAs (mRNAs) must be tightly regulated to prevent aberrant 
synthesis of proteins that could lead to anomalous development and eventual disease [1–3]. Regulation 
of mRNAs is thereby achieved by different RNA-binding proteins (RBPs) and non-coding RNAs, such 
as microRNAs (miRNAs), which interact with distinct elements in the mRNA, forming so-called 
ribonucleoprotein (RNP) complexes [4]. Different RNPs dynamically rearrange through the life cycle of an 
mRNA [4,5]. Upon synthesis of nascent transcripts by RNA polymerase in the nucleus, mRNA-precursors 
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(pre-mRNAs) become immediately assembled with a host of proteins, which perform processing 
events such as capping, splicing, editing and polyadenylation [6]. Matured mRNAs are then exported to 
the cytoplasm by a variety of export factors and are localized to specific subcellular regions [7]. In the 
cytoplasm, mRNAs can be stored or captured by translation factors for assembly with ribosomes to serve 
as templates for protein synthesis. Thus, translation can be regulated by global means through translation 
initiation factors, while specific RBPs or miRNAs can modulate the control selected mRNAs [8]. 
Finally, transcripts are degraded through exonuclease-mediated degradation pathways and specific 
RBPs/miRNAs can direct specific degradation programs to subsets of mRNAs [4]. 
RBPs contain one or several characteristic RNA-binding motifs that specifically interact with  
RNA [5,9–11]. Some well-characterised RNA-binding domains refer to the RNA-recognition motif 
(RRM), the K-homology (KH) domain, the zinc finger motif (ZnF), the double stranded RNA-binding 
domain (dsRBD), and the Pumilio/FBF (PUF or Pum-HD) domain. Notably, RBPs often contain an 
array of the same or different RNA-binding motifs, which increases their specificity and affinity 
towards the RNA. Cytoplasmic RBPs preferentially interact with sequences or structural elements 
located in the 3'-untranslated region (3'-UTR) of mRNAs, allowing targeting of a subset of mRNAs to 
implement specific control. Importantly, the application of global analysis tools to comprehensively 
identify the mRNA targets for RBPs has revealed that RBPs preferentially bind to mRNAs coding for 
functionally related proteins—forming post-transcriptional operons or RNA regulons enabling coordinated 
control of mRNA expression [10–13]. 
mRNAs are also regulated via physical interactions with non-coding RNAs (ncRNA). Arguably, the 
best-characterised small ncRNAs (200 nts in length) are the microRNAs (miRNA), ~22-nucleotides (nts) 
long RNA molecules that negatively regulate gene expression in metazoans, with important roles in 
cancer development, progression and metastasis [14–17]. The production of miRNAs is complex and 
assisted by different RBPs [18]. Initially, miRNAs are transcribed as longer transcripts, so called 
primary miRNAs (pri-miRNA), which are then processed to precursor miRNAs (pre-miRNAs) 
involving the RNAse III protein Drosha. After export to the cytoplasm, pre-miRNAs are converted 
into mature miRNAs by Dicer (another RNAse III protein) and assemble with members of the 
Argonaute (Ago) protein family into the miRNA-induced silencing complex (miRISC). Of note, the 
maturation of particular miRNAs is further controlled by specific RBPs that bind to pri-miRNA or  
pre-miRNA sequences and thereby facilitate or block their maturation [18]. The miRISC complex then 
assembles with sequences located mostly in the 3'-UTRs of target mRNAs and induces changes in the 
subcellular localization, translation efficiency and stability [18]. The rules of miRNA-target recognition 
are still not fully understood yet. One important determinant relates to a requirement for perfect 
complementarity between the target site and 7–8 nucleotides at the 5'-end of the miRNA (region 
known as miRNA “seed”), while nucleotides further downstream (nucleotides 13–16) can also contribute 
to base pairing with the mRNA target [18,19]. In addition to miRNAs, an increasing number of long 
ncRNA (>200 nts) have also been recognized to regulate cytoplasmic translation events, such as the 
brain cytoplasmic (BC) family of lncRNAs, which regulate mRNA translation in neurons through 
interaction with translational initiation factors [20]. 
Bioinformatic searches have predicted more than one thousand RBPs (1542) [5], and almost double 
that number of miRNAs (2588) in the human genome [21]. Due to their vast numbers, it is not a great 
surprise that computational analysis predicted substantial combinatorial control of mRNA fates 
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through simultaneous assembly of RBPs and miRNAs on particular mRNAs (e.g., [22]). Thus, looking 
at single proteins or the action of distinct miRNAs on mRNA fates alone could be misleading, as it 
does not consider the entire arrangement of trans-acting regulatory factors that affect specific mRNAs. 
Moreover, the differential expression of RPBs and miRNAs can lead to condition-specific assemblies 
restricted to particular cell-types or subcellular compartments. In this review, we discuss recent examples 
that support the notion of extensive combinatorial post-transcriptional control of mRNA stability and 
of translation through interactions with RBPs and/or miRNAs. We focus on recent mechanistic studies 
exemplifying antagonistic or synergistic arrangements of: (i) RBPs and miRNAs; (ii) RBPs and RBPs 
and (iii) miRNAs on cytoplasmic mRNAs and their impact in cell biology. 
2. Cross-Talk between RBPs and miRNAs on Cytoplasmic mRNAs 
An expanding number of reports demonstrate the interplay between miRNAs and RBPs on target  
3'-UTRs under specific conditions. We highlight here some of the examples with direct implications in 
oncogenesis or cell differentiation, and the reader is referred to recent reviews highlighting additional 
studies [19,23–25]. Notably, most examples reported to date involve HuR, a member of the embryonic 
lethal abnormal vision (ELAV) family of proteins, which have wide-ranging roles in stabilizing mRNAs 
in the cytoplasm by binding to AU-rich elements (ARE) preferentially located in the 3'-UTRs [26]. 
Whereas HuB, HuC, and HuD are neuronal or gonadal proteins, HuR is ubiquitously expressed and 
mediates cellular responses to different types of stress and coordinates inflammatory responses. HuR 
has been correlated with tumorigenesis in different cancer types, like breast, ovarian, colon, lung, and 
prostate cancer and in mesothelioma [27–34]. Moreover, HuR becomes predominantly cytoplasmic in 
certain tumour cells and correlates with decreases in patient survival rates [27]. 
Several examples relate to the competition between an RBP and a miRNA for a particular binding 
site on an mRNA, resulting in antagonistic effects (Figure 1a (i–iii)). First described by Filipowicz and 
colleagues, HuR can relieve cationic amino acid transporter 1 (CAT1) mRNA from miR-122 mediated 
repression under stress conditions in human hepatoma carcinoma cells [35]. Upon amino-acid starvation, 
which triggers a cellular stress response, nuclear HuR is dephosphorylated and it translocates to the 
cytoplasm, where it binds to an ARE element in the 3'-UTR of CAT-1 mRNA and thereby relieves the 
inhibition exerted by miR-122. HuR then stabilizes the CAT-1 mRNA and enhances its translation by 
redirecting the mRNAs from processing (P) bodies (where mRNAs are degraded) to polysomes for 
protein synthesis (Figure 1a (i)) [35]. However, whether this is accompanied by the dissociation of 
miRNPs from the mRNA or just prevents miRNPs from acting as effectors in the repression remains to 
be established [35]. In colon cancer cells the expression of mRNAs coding for the pro-inflammatory 
enzyme cyclooxygenase-2 (COX-2) is controlled by direct competition between HuR and miR-16 for 
an overlapping binding site located in the 3'-UTR of the mRNA [36]. COX-2 is a key enzyme that 
converts arachidonic acid to prostaglandins with implications in tumour progression, and it is thus a prime 
target for cancer treatment (Figure 1a (ii)) [37]. In non-tumour cells, HuR is mainly localised in  
the nucleus, allowing miR-16 to suppress COX-2 expression; however, the redirection of HuR to the 
cytoplasm in colon cancer cells leads to the stabilisation of COX-2 mRNA through binding to an ARE 
element, making it less accessible to miR-16 [36]. Similarly, HuR controls receptor tyrosine kinase 2 
(ERBB-2) mRNA in prostate cancer cells (Figure 1a (iii)) [32]. Thus, HuR interacts with the 3'-UTR  
Biomolecules 2015, 5 2210 
 
 
of ERBB-2 and blocks, likely through steric hindrance, the association of two miR-331-3p/RISC molecules 
adjacent to the HuR binding site, leading to the stabilisation of ERBB-2 mRNAs [32]. The accumulation  
of ERBB-2 in prostate cancer cells leads to the activation of signalling pathways, such as the 
phosphatidylinositol-3-kinase (PI3K)/AKT signalling pathway, which correlates with cancer progression 
and therapy resistance. 
Related to HuR, the dead end 1 (DND1) protein also counteracts miRNA function by binding to U-rich 
regions in the 3'-UTR of mRNAs [38]. This finding from the Agami group was based on the observation 
that it was not only the miRNA-targeting site in mRNAs that was conserved throughout evolution but 
also sequences that flanked it and that these could provide a binding platform for RBPs. Such conservation 
has been observed between two miRNA-targeting sequences for miR-221/222 and miR-372 in the  
3'-UTRs of mRNAs coding for the tumour suppressors cyclin-dependent kinase inhibitor 1B (CDKN1B, 
also known as p27) and large tumour suppressor kinase 2 (LATS2), respectively (Figure 1a (i)). A reporter 
based expression screen identified DND1 binding to this conserved region and it was shown that 
DND1 antagonises miRNA-mediated repression by preventing the respective miRNAs from binding to 
the transcripts by reducing the miRNA accessibility [38]. While the above examples concern 3-UTRs of 
mRNAs, there is at least one example related to antagonistic roles within coding sequences (CDS) [39]. 
The inherent instability of -transducin repeat-containing protein 1 (-TrCP1) mRNA is caused  
by miR-183 targeting the coding sequence, however, the coding region determinant-binding protein  
(CRD-BP) prevents degradation of -TrCP1 mRNA by attenuating its miR-183-dependent interaction 
with Ago2 (Figure 1a (ii)) [39]. 
In addition to these antagonistic modes, RBPs and miRNAs can also cooperate to achieve repression 
of a common mRNA target, resulting in synergistic effects [25,40–42]. The Gorospe laboratory described 
strong interdependence between HuR and let-7 to repress the mRNA coding for the proto-oncogene  
c-Myc: as let-7 requires HuR to reduce c-Myc expression; HuR also requires let-7 to inhibit c-Myc 
expression (Figure 1a (iv)). This suggested a regulatory paradigm wherein HuR recruits let-7-loaded 
RISC to the 3'-UTR to inhibit c-Myc expression [40]. Since miRNA silencing is dependent on the 
accessibility of single-stranded RNA target sequences, local RNA structures could sterically hinder the 
binding of the miRISC complex. Such a mode of action has been experimentally confirmed for human 
Pumilio (PUM) protein that binds to a sequence element in the 3'-UTR of p27 mRNA and induces a 
local change in the RNA structure that favours association with specific miRNAs such as miR-221/miR-222 
(Figure 1a (v)) [41]. High levels of miR-221 and miR-222 are seen in many cancer cell types, which 
inhibit the expression of p27 and stimulate cell proliferation. In response to growth factor stimulation, 
PUM1 is phosphorylated, resulting in increased RNA-binding activity towards the p27 3'-UTR, which then 
favours association of miR-221 and miR-22 for efficient suppression of p27 expression, enabling a 
rapid entry into the cell cycle. Likewise, a RBP-induced structural switch modulating miRNA-mediated 
gene expression by PUM proteins has also been described on mRNAs coding for oncogene E2F 
transcription factor 3 (E2F3), which is strongly repressed by the cooperative action of miR-506 and 
PUM1 in bladder carcinoma cells [42]. Increased expression of E2F3 is correlated with the down-regulation 
of mRNAs bearing a shorter 3'-UTR that does not contain the PUM1 binding site (Figure 1a (v)). 
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Figure 1. (a) Schematic of crosstalk between miRNAs and RBPs. Upper panel: The 
antagonistic interplay between RBPs with a mRNA target prevents miRNAs from binding 
to the transcript. RBP binding can occur next (i) to the miRISC binding site, in between (iii), 
or overlap in 3'-UTRs or coding sequences (CDS) (ii). Middle panel: Cooperation achieved 
by RBPs that promote/enable miRISC binding to mRNA targets (iv), thereby altering local 
RNA structures (v). Lower panel: Antagonistic and synergistic interplay between RBPs, 
where the miRISC activity on the same mRNA is determined by different combinations of 
RBPs; (b) Scheme of crosstalk between RBPs and RBPs. Upper panel: Competition of two 
RBPs for distinct (i) or the same (ii) RNA binding site. Translation initiation factors competing 
for common feature on the mRNA (cap) (iii). Middle panel: Cooperation between RBPs that 
promote mRNA export and translation (iv), Lower panel: Complex antagonistic and 
synergistic interplay between RBPs exemplified on VEGFA mRNA (v); (c) Scheme of 
crosstalk between miRNAs-miRNAs. Upper panel: Cooperation between different miRISC 
to enhance the inhibition of expression of the mRNA target (i). Lower panel: Competition 
between different miRISC to enhance the expression of the mRNA target (ii). 
In contrast to the above studies, where specific RBPs either positively or negatively regulate 
miRNA targeting, a more recent study revealed the combination of both regulatory modes [43]. The 
pyrimidine-tract binding (PTB) protein either suppresses or enhances miRNA targeting by competitive 
binding on target mRNA or by altering local RNA secondary structure [43]. Particularly, it was shown 
that PTB directly competes with miRNAs on multiple targeting sites in the 3'-UTR of the small  
C-terminal domain phosphatase 1 (SCP1) transcript, whereas PTB binding modulates the secondary 
structure of the glucosamine-6-phosphate deaminase 1 (GNPDA1) 3'-UTR to facilitate let-7b binding 
(Figure 1a (v)). The interplay of the two modes, antagonistic and synergistic, with miRNA regulation 
could occur at different locations of the same transcript and the net additive effect may dictate the final 
outcome. Furthermore, PTB—better known for its role in splicing—seems to have a rather broad role 
in gene expression through functional interplay with the miRNA machinery. PTB, thus, has critical 
impact for cell fate as the reprogramming of splicing and miRNA levels induced through regulated 
PTB expression can drive cell fate decision towards the neuronal lineage [43]. 
The combinatorial control of mRNAs by ncRNA and RBPs has also been documented in differentiated 
neurons, where an even more complex mode of regulation has been discovered that involves two  
RBPs [44]. It concerns the fragile X mental retardation 1 protein (FMRP1), a well-characterised RBP 
with roles in mRNA transport and in the regulation of translation/ stability of mRNAs in neurons, and 
whose functional ablation causes Fragile X syndrome [45]. Using a transcriptome-wide approach to 
identify mRNA targets with iCLIP, the Ceman group identified the relationship between FMRP and 
Moloney Leukemia Virus 10 protein (MOV10) in modulating miRNA-mediated translational repression of 
several mRNAs, such as myc-associated zinc finger protein (MAZ) and MHSC1 [44]. MOV10 is an 
RNA helicase that unwinds GC-rich secondary structures close to miRNA binding sites in the 3'-UTR 
of mRNAs, enabling the assembly of miRISC complex which leads to translational repression of the 
mRNA target (Figure 1a (vi)). Interestingly, the resulting regulatory mode comprises two RBPs that 
control the action of proximal miRNAs. In the case where the FMRP binding site does not overlap 
with the MOV10 binding site, FMRP facilitates MOV10 binding to the mRNA and consequently, 
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miRISC association with the mRNA for translational suppression. Conversely, in the case where the 
FMRP binding site overlaps with the MOV10 binding site, the respective mRNA is protected from 
translational suppression by miRNAs because MOV10 cannot bind to the mRNA and the formation of 
the miRISC complex is abolished [44]. 
In addition to the above examples, verified experimentally, a series of computational analyses have 
predicted cross-talk between RBPs and miRNA-mediated repression of human mRNAs [22,46]. For 
instance, global investigation of PUM mRNA targets in human cancer cells revealed that PUM 
recognition elements (PREs) are enriched around high-confidence miRNA binding sites in the 3'-UTRs 
of experimentally determined human PUM mRNA targets, suggesting interaction of PUM proteins 
with the miRNA regulatory systems [47]. It was also suggested that mRNAs that contain PREs in the 
proximity of predicted miRNA-binding sites are predicted to form stable secondary structures within 
their respective 3'-UTRs, and that PUM proteins are likely to be general regulators of miRNA 
accessibility [48]. A recent computational analysis exploring the potential cross-talk between RBPs, 
such as PUM proteins, and miRNA-mediated repression of human mRNAs identified a specific group 
of miRNA (miR-30-abcde/385-5p, miR-144, miR-376c, miR-300, miR-101, miR-221/222, and miR-410) 
binding sites overrepresented near PUM recognition sites in the 3'-UTR, suggesting strong cooperation 
to control the decay of these mRNAs [22]. Global analysis of HuR mRNA targets using photoactivatable 
ribonucleoside crosslinking and immunoprecipitation (PAR-CLIP) and RBP immunoprecipitation 
sequencing (RIP-seq) revealed the enrichment of HuR binding sites proximal to or overlapping with 
miRNA recognition sites [49]. Furthermore, depletion of either HuR or of 25 highly expressed miRNAs 
in HEK293 cells revealed that the levels of mRNA targets, with predicted overlapping miRNA and 
HuR binding sites, were less “upregulated” than transcripts with non-overlapping binding sites, 
suggesting that HuR-binding is likely to lead to the relief of miRNA-mediated regulation by competing for 
binding [49]. In the future, the combination of computational analysis and experimental verification 
will certainly reveal additional examples of interesting cross-talk between RBPs and classes of miRNAs, 
and it could disclose the extent of the respective modes of regulation at a global level. 
As seen across these studies, the modes of cross-talk between RBPs and miRNAs are manifold and 
no common principle can be established. Besides the relatively “simple” models described in early 
studies, which referred to the competition of RBPs and miRNAs for binding sites in the mRNA 
resulting in antagonistic effects, the more recent studies have revealed more complex models, 
including synergistic effects implied by the modulation of local RNA structures to small regulatory 
networks that comprising additional components, e.g., additional RBPs. In this respect, while multiple 
examples describe the trans-interaction of RBPs and mRNAs to enable miRNA functions (e.g., collaboration 
of RBPs to enable miRISC assembly and activity), we are not aware of experimentally verified examples 
that describe the opposite, trans-interactions between miRNAs and mRNAs for controlling binding of 
specific RBPs to mRNAs. Interestingly, it was postulated that the assembly of miRNAs on mRNA 
could create 3-way RNA junctions, splinting two non-contiguous regions in the mRNA together, which 
could lead to the formation of a stem-loop structure targeted by certain RBPs [50]. In this model, miRNAs 
could interact with mRNAs and thereby change or stabilise the RNA conformation and consequentially 
modulate the accessibility of RBPs [50]. Furthermore, some evidence for trans-interactions has been 
obtained for long ncRNAs that could anneal with specific mRNAs in the cytoplasm forming extended 
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regions of double-stranded RNA, which may provide an interaction platform for dsRNA-binding 
proteins to mediate regulatory functions [51]. 
3. Interplay of RBPs on mRNA Targets 
There are numerous examples of combinatorial binding of RBPs resulting in specific splicing 
decisions [52–54]; however, much less is known about combinatorial control exerted by cytoplasmic 
RBPs to modulate mRNA stability or translation. The hitherto recognised events involve remodelling of 
RBPs activity in response to internal/ external stimuli, which are often accompanied by post-translational 
modifications of proteins that could affect the affinity to mRNA targets or alter their subcellular 
localisation [10]. 
Most investigations have focussed on AU-rich element binding proteins, such as HuR, which 
compete for binding to the same or different motifs in 3'-UTRs of particular mRNAs. An early study 
described the post-transcriptional regulation of eukaryotic translation initiation factor 4E (eIF4E)  
(the cap-binding protein), whose levels are highly elevated in many human cancers. HuR and the p42 
isoform of AU-binding factor 1 (AUF1) compete for binding to the 3'-UTR of eIF4E mRNA at  
non-overlapping sites (Figure 1b (i)) [55]. A distinct AU-rich element in the 3'-UTR of eIF4E was 
found to be responsible for HuR-binding and stabilisation of the mRNA and could correlate with 
enhanced expression of eIF4E and HuR in malignant cancer specimens [55]. However, more common 
are antagonistic effects accomplished by competition at overlapping RNA binding sites [56,57].  
It has been described for HuR and the ARE-binding protein Tristetraprolin (TTP), where the 
phosphorylation-dependent exchange of TTP and HuR provides a reversible switch between unstable 
and stable/efficiently translated mRNAs [56] (Figure 1b (ii)). Expression of tumour necrosis factor  
(TNF) mRNAs is regulated post-transcriptionally upon activation of the inflammatory response by the 
p38 MAPK/MK2/3 signalling pathway. Activation of this pathway leads to the phosphorylation of 
HuR, which becomes predominantly localised to the cytoplasm; phosphorylation of TTP decreases its 
affinity to ARE binding sites in the 3'-UTR of mRNAs. These phosphorylation events allow HuR to 
bind to the AREs routinely bound by TTP, and thus HuR further stabilises and promotes the translation 
of TNF mRNA. Interestingly, translation of TTP mRNA is similarly regulated, which could shape an 
intrinsic feedback loop to control the extent of the inflammatory response [56]. Notably, a recent 
global survey of the mRNA targets for HuR and TTP unravelled thousands of overlapping TTP and 
HuR binding sites, suggesting that combinatorial control by these proteins likely occurs for a large 
number of mRNAs [58]. Likewise, a recent study showed that HuR competes with the RBP Elav-like 
family member 1 (CELF1) to regulate the expression of MYC mRNA [57]. Importantly, the antagonistic 
effects could play an important role in the self-renewal of the epithelium in the mammalian intestinal 
mucosa, which essentially depends on MYC activation. It could be shown that in polyamine depleted 
cells—the supply of polyamines controls epithelium renewalCELF1 antagonizes HuR by binding the 
same element in the 3'-UTR of the MYC transcript, causing inhibition and consequentially a decrease 
in MYC protein levels (Figure 1b (ii)). 
There are only a few cases describing “pairs” of RBPs that cooperate and dictate a translational 
response or mRNA stability. One recent study described the post-transcriptional regulation of p53 
mRNA by two RBPs, the hematopoietic zinc finger protein (Hzf) and HuR, which occurs in response 
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to signals that induce p53 activation by the tumour suppressor protein ARF (alternative reading frame). 
Hzf and HuR independently associate with the 3'-UTR of p53 mRNA, which facilitates nuclear export 
and translation (Figure 1b (iv)) [59]. Extensive combinatorial control by RBPs and miRNAs occurs at 
vascular endothelial growth factor-A (VEGFA) mRNAs upon external stimuli [60,61]. VEGFA has 
been identified as the predominant tumour angiogenesis factor in the majority of human cancers, 
including those of the breast, colon, lung and prostate, and thus is a major target for cancer treatment and 
drug development. Hypoxia, which is one of the main characteristics of the tumour microenvironment, 
induces VEGFA expression by increasing transcription, translation, and mRNA stabilisation.  
Post-transcriptional regulation of VEGFA involves different mechanisms, including the binding of 
cytoplasmic HuR to an ARE element in the 3'-UTR of VEGFA which increases mRNA stability 
(Figure 1b (v)) [62]; the reversal of miRNA-mediated silencing of VEGFA expression by RBPs [61]; 
and the cross-talk among different RNA-binding complexes on the mRNA [60,63]. The cross-talk 
occurs in a CA-rich element (CARE), localised in the 3'-UTR of VEGFA and it serves as a central hub 
for assembly and execution of regulatory events. On the one hand, the CARE is targeted by at least 
four different miRNAs (miR-297, miR-299, miR-567, and miR-609) and by the heterogeneous nuclear 
ribonucleoprotein L (hnRNP L). Since hypoxia induces the translocation of nuclear hnRNP L to the 
cytoplasm, this excess of hnRNP L will compete with those miRNAs for VEGFA mRNA binding and 
therefore inhibit miRNA mediated repression [61]. Additionally, hnRNP L binding induces local 
changes in the mRNA structure, which prevents the access of another inhibitory protein complex, the 
IFN- activated inhibitor of translation complex (GAIT) (Figure 1b (v)) [60]. Further investigation 
revealed that the so-called HILDA (hypoxia-inducible hnRNP L–DRBP76–hnRNP A2/B1) complex 
coordinates a three-element RNA switch, enabling VEGFA mRNA translation during concomitant 
hypoxia and inflammation [63]. 
Competition between RBPs can also occur for common mRNA features such as the m7G cap 
structure present at the 5'-end of eukaryotic mRNAs. Cap-dependent translation is conducted by the 
co-operation between translational factors, where eIF4E1 is the main cap binding protein [64]. 
Recently, Lee and co-workers described how hypoxia induces a selective competition between the two 
related cap binding proteins (eIF4E1 and eIF4E2) [65]. Under normal oxygen conditions (normoxia), 
eIF4E1 binds to the m7G cap at the 5'-end of mRNAs forming a complex with eIF4A, eIF3 and eIF4G 
and other translational factors to initiate translation. However, when cells are grown under hypoxic 
conditions (oxygen levels ~1%), an alternative complex is formed at the cap structure of mRNAs which 
contain an RNA Hypoxia Response Element (rHRE) in the 3'-UTR, such as in the epidermal growth 
factor receptor (EGFR) mRNA. This alternative complex comprises the cap-binding protein eIF4E2, 
oxygen-regulated hypoxia-inducible factor-2alpha (HIF-2) and the RNA-binding protein 4 (RBM4). 
It was concluded that during hypoxia, cap-dependent translation of rHRE containing transcripts is 
eIF4E2-mediated [65]. This finding suggests that different initiation complexes may coexist in cells, 
competing with each other to direct the translation of subsets of mRNAs (Figure 1b (iii)). 
4. Cross-Talk among miRNAs 
It has been recognised for some time that miRNAs can work in concert to enhance the inhibition of 
expression of a mRNA target (Figure 1c (i)) [66–68]. Different pools of miRNAs may possess the 
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ability to target a given transcript simultaneously, but in reality, this depends on the presence of the 
miRNAs in the same place at the same time, and miRNA expression is not uniformly distributed 
within different tissues and tumours [66–68]. For example, in prostate cancer, expression of the tensin 
homologue deleted on chromosome 10 (PTEN) transcripts is effectively repressed by the combined 
action of miR-106b, miR-93 and miR-25 [66]. Conversely, in breast cancer cells, PTEN expression is 
inhibited by another miRNA family namely miR-302 [69]. Since PTEN represses the activation of the 
PI3K/AKT/mTOR signalling pathway, decreased PTEN expression mediated by miRNAs leads to the 
activation of the PI3K/AKT/mTOR pathway, which then drives tumour progression and metastasis in 
many types of cancer [70]. Other related examples include the miR-182, miR-146a, and miR-146-5 
that additively accomplish repression of the breast cancer-associated 1 (BRCA1) mRNA in breast 
cancer cells [67]; and the cooperation between let-7 and miR-125 miRNA families that target a set of 
mRNAs such as insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2) and pleomorphic 
adenoma gene-like 2 mRNA (PLAGL2) during the neurogenic to gliogenic transition in glial 
progenitor cells (Figure 1c (i)) [68]. 
In contrast to what has been described above, little is known about antagonistic interactions among 
miRNAs. Lavker and colleagues [71] have described the first example where miRNA negatively 
regulates another miRNA to maintain levels of a target protein. Besides demonstrating that lipid 
phosphatase SH2-domain-containing inositol 5-phosphatase 2 (SHIP2) is a target of miR-205 in epithelial 
cells, they observed that the corneal epithelial-specific miR-184 interferes with miR-205 to suppress 
SHIP2 levels [71] (Figure 1c (ii)). Since aggressive squamous cell carcinoma (SCC) cells exhibited 
elevated levels of miR-205, they speculated that blockage of miR-205 activity with an antagonist or 
via ectopic expression of miR-184 could establish a therapeutic approach for treating aggressive SCCs. 
5. Conclusions and Final Remarks 
Although there are only a small number of experimentally established examples of combinatorial 
control of mRNA fates by RBPs and miRNAs, the total number of such events may be massive 
considering the hundreds of RBPs and thousands of miRNAs that are present in eukaryotic cells. In this 
regard, the recent establishment of a variety of easily accessible databases and web-based search portals 
provide helpful tools to perform in silico analyses to identify potential combinatorial events. For instance, 
several databases offer the possibility to scan a given RNA sequence for potential RNA binding sites 
of RBPs and conversely, to search for known or predicted RNA targets of a given RBP or miRNA 
(e.g., for RBPs: [72–77]; for miRNAs (e.g., [78,79]). This analysis can be extended to different organisms, 
providing information about the evolutionary conservation of particular RNA binding sites. In addition, 
potential binding partners related to human disease may be recognised by correlating the expression of  
a particular miRNA [80,81] or long noncoding (lncRNA) with human pathology (e.g., [82,83]). Using 
these and other bioinformatics tools, new post-transcriptional regulatory events could be deduced for 
further experimental testing, and possibly set a framework for the discovery of new diagnostic markers 
in disease. 
Furthermore, it should be noted that the post-transcriptional regulators themselves undergo extensive 
regulation at the post-transcriptional level. RBP expression can be regulated by specific miRNAs or 
other RBPs, which could result in the modulation of effects exerted on the respective RBP-controlled 
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genes (reviewed in [24,25]). It has been recognised for some time that RBPs tend to bind to messages 
coding for regulatory proteins such as RBPs and transcription factors (TFs) conceptualising a 
“regulator-of-regulator” role which is reflected by very dense post-transcriptional networks among 
RBPs seen in global RNA-protein interaction networks and supported by direct experimental evidence 
[10,84,85]. Regarding the latter, it was shown that a group of ARE-binding proteins (HuR, AUF-1, 
TIA1, KSRP) is controlled, at least in part, at the posttranscriptional level through a complex circuitry of 
self- and cross-regulatory RNP interactions [85]. Conversely, the interplay of RBPs can also directly 
modulate the biogenesis or localisation of miRNAs (reviewed in [24,25,86]). For instance, the Cáceres 
laboratory highlighted the crosstalk between heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) 
and KH-type splicing regulatory protein (KSRP). KSRP and hnRNP A1 compete for binding to the 
terminal loop of let-7a pre-miRNAs, which promotes or blocks pre-miRNA processing in somatic cells, 
respectively [87]. To complete the picture, it is tempting to speculate that miRNAs may also regulate 
the biogenesis, localisation or activity of other miRNAs. However, to our knowledge, such a strategy 
has not been experimentally verified. 
In the light of the immense potential for combinatorial control of cytoplasmic mRNA fates, the 
further development of biochemical and cell-biology techniques that enable the tracking of a particular 
mRNA molecule in cells will be key to obtain a more comprehensive picture of when and where RBPs 
and ncRNAs interact with particular mRNAs for post-transcriptional control. Whereas the studies 
outlined above mainly approached combinatorial control from the context of the trans-acting factors 
by predicting/experimentally confirming crosstalk on mRNA targets by global or specific means, the 
converse approach, which involves the isolation of particular mRNAs from cells for inspection of the 
assembly of trans-acting factors, lags behind. For instance, the comparative biochemical isolation of 
particular mRNAs from cells or tissues at different developmental stages, upon activation of particular 
pathways or from pathological samples (e.g., cancer), could lead to a refined understanding of the dynamics 
and extent of RNP remodelling, and the elucidation of novel regulatory circuits that may be implicated 
in human disease. 
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